Optimizing CAR-T therapy delivery in the Italian healthcare system: economic and organizational insights in follicular lymphoma [0.03%]
CAR-T疗法在意大利医疗体系中的交付优化：滤泡性淋巴瘤的经济和组织学见解
Andrea Vitagliano,Marzia Bonfanti,Emanuele Angelucci et al.
Andrea Vitagliano et al.
Introduction: Follicular Lymphoma (FL) is the second most common lymphoid malignancy, with 20% of patients progressing within 24 months of first-line therapy. Chimeric antigen receptor T-cell (CAR-T) therapies have improv...
La riforma AIFA e i tempi di valutazione dei nuovi farmaci: l’impatto della nuova Commissione Scientifica ed Economica del Farmaco [0.03%]
意大利AIFA改革及新药评估周期的变化：新药物科学与经济委员会的影响
Benedetta Dal Canto,Vera Benedetto,Alma Martelli et al.
Benedetta Dal Canto et al.
Introduction:: Timely access to new medicines is a key dimension of health system performance. In Italy, pricing and reimbursement decisions are taken by the Italian Medicines Agency (AIFA). In 2024, a reform established ...
More and earlier data from AIFA: do they impact on the regional policies? Results from an exploratory analysis [0.03%]
来自AIFA更多的和更早的数据：它们会对地区政策产生影响吗？探索性分析结果
Riccardo Novaro,Mattia Altini,Francesca Futura Bernardi et al.
Riccardo Novaro et al.
Introduction: In Italy, drug prices and reimbursement are managed by the Italian Medicines Agency (AIFA), but regions actually enable patient access to medicines. Our aim is to provide evidence on (i) the current manageme...
Cost minimization analysis of subcutaneous and intravenous immunoglobulin treatment in Italy [0.03%]
意大利皮下注射和静脉注射免疫球蛋白治疗的最小成本分析
Chiara Bini,Matteo Scortichini,Silvia Ripoli et al.
Chiara Bini et al.
Introduction: Human immunoglobulins are the standard of care for patients with immunodeficiencies and represent a first-line treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). This study aimed to eval...
Raúl Ortiz de Lejarazu,Esther Redondo Margüello,Ángel Gil de Miguel et al.
Raúl Ortiz de Lejarazu et al.
Introduction: Influenza vaccines are formulated each year to prevent serious illness in at-risk individuals, including elderly people. Healthcare decision-making is mainly based on the economic evaluations (EEs) (i.e., co...
Ridiscussioni nel processo decisionale dell’Agenzia Italiana del Farmaco: una valutazione quantitativa di cause e implicazioni [0.03%]
意大利药物管理局决策过程中的重新讨论：原因及影响的定量评估
Michele Caimmi,Beatrice Canali,Anita Ciarlo et al.
Michele Caimmi et al.
Introduction:: Until 2024, Pricing and Reimbursement (P&R) requests for medicinal products in Italy were assessed by two separate bodies within AIFA: at first by the Technical Scientific Committee (CTS), then by the Prici...
Italian Medicines Agency's reform and time until pricing and reimbursement decisions: a time-to-event analysis [0.03%]
意大利药品机构改革及至定价和报销决定的时间分析
Gian Marco Raspolini,Bruno Federico,Mario Cesare Nurchis et al.
Gian Marco Raspolini et al.
Introduction: The duration of pricing and reimbursement (P&R) negotiations is a key performance indicator for medicines agencies in universal health coverage systems. In early 2024, the Italian Medicines Agency (AIFA) und...
Come le Regioni possono utilizzare il Rapporto OsMed per condividere le azioni di miglioramento dell’appropriatezza [0.03%]
地区如何利用OsMed报告分享适宜性改进行动的经验教训
Silvia Sansone,Maria Cristina Carena,Giorgia Fedele et al.
Silvia Sansone et al.
Introduction:: Italy retains a unique wealth of information on drug usage, embodied in the OsMed Report, published since 2001 and based on data collected by the National Observatory on the Use of Medicines. The Report ana...
Non-profit research: an insight into the management and monitoring of clinical trials in Italy [0.03%]
意大利临床试验的管理和监管透视——非盈利性研究机构的视角
Fatima Tizi,Viviana Appolloni,Barbara Bonifacio et al.
Fatima Tizi et al.
Introduction: In January 2022, Italy fully implemented EU Regulation No. 536/2014, revolutionizing the national framework for clinical research on medicinal products. This marked a critical shift for non-profit sponsors, ...
The societal costs associated with patients with chronic spontaneous urticaria (CSU) in Italy [0.03%]
意大利慢性自发性荨麻疹（CSU）患者的社ysical和社会成本
Chiara Bini,Andrea Marcellusi,Virginia Scansetti et al.
Chiara Bini et al.
Introduction: Chronic spontaneous urticaria (CSU) is a debilitating dermatological disease. The study aimed to estimate the indirect costs and out-of-pocket expenses incurred by CSU patients in Italy. ...